Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALN-TTRSC (revusiran) in transthyretin-mediated familial amyloidotic cardiomyopathy
2014-003835-20Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2014
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial amyloid cardiomyopathy (FAC) and familial amyloidosis comparing Revusiran (ALN-TTRSC) with Placebo (2 arms). Started Oct 2014; status: completed.
02
Drugs
revusiran
03
Conditions
familial amyloid cardiomyopathy (FAC)familial amyloidosis
Beyond the preview
Go deeper on 2014-003835-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003835-20.